Key Highlights
- FDA has granted approval for Merck’s Lipfendra (enlicitide), marking the debut of a once-daily oral PCSK9 inhibitor targeting elevated LDL-C
- Clinical trials demonstrated Lipfendra reduced LDL-C by 60%, with no severe adverse events documented
- At $315 monthly, Merck undercuts injectable competitors that command prices exceeding $500 per month
- Financial analysts forecast Lipfendra could generate over $350 million in 2027, with long-term annual potential reaching $5 billion
- Following encouraging Keytruda partnership trial results, Guggenheim maintained its Buy recommendation with a $145 target on MRK
Shares of Merck climbed approximately 1% during premarket hours Thursday, reaching $125, following the FDA’s ahead-of-schedule approval of Lipfendra—the inaugural oral PCSK9 inhibitor—under the regulatory body’s accelerated review pathway. Year-to-date in 2026, the stock has advanced roughly 18%.
This regulatory clearance represents a significant achievement for Merck. Marketed as Lipfendra, enlicitide becomes the first tablet formulation capable of blocking PCSK9, a protein responsible for regulating LDL-C—widely recognized as “bad cholesterol.” Previously, PCSK9 blockers existed solely as injectable therapies.
Heart-related illnesses remain the primary mortality driver worldwide and contribute to approximately 25% of fatalities in the United States. While statins have served as the standard treatment approach since the 1980s, they prove inadequate for numerous patients, especially individuals with genetically-driven elevated cholesterol.
Clinical trial data from two studies revealed Lipfendra decreased LDL-C concentrations by 60%. Researchers identified no significant safety concerns, although approximately 7% of participants experienced diarrhea. An extended investigation monitoring cardiovascular events including heart attacks and strokes remains in progress and isn’t scheduled to conclude until 2029.
Market Competition and Pricing Strategy
Merck is launching into a therapeutic space currently dominated by injectable PCSK9 medications. Amgen’s Repatha recorded $900 million in first-quarter 2026 revenue, representing 34% year-over-year growth. Novartis’s Leqvio contributed $400 million during the identical timeframe, marking a 76% increase. Regeneron’s Praluent achieved $260 million in 2025 U.S. sales.
With a monthly list price of $315, Lipfendra offers compelling value compared to injectable alternatives commanding over $500. Merck announced commercial distribution will commence within several weeks.
Wall Street analysts anticipate Lipfendra could surpass $350 million in sales during the coming year, with extended-term revenue potentially hitting $5 billion yearly assuming robust market adoption.
The medication also holds considerable strategic importance. Keytruda, Merck’s dominant oncology franchise producing $32 billion in yearly revenue, faces patent expiration in 2028. Lipfendra represents a key asset in Merck’s portfolio strategy to bridge that impending revenue shortfall.
Positive Keytruda Development News
In related developments, Guggenheim confirmed its Buy stance and $145 valuation target for MRK Thursday, highlighting successful Phase 3 results from collaborator Kelun-Biotech. The study evaluated Kelun’s TROP2-targeting ADC sacituzumab tirumotecan paired with Keytruda in treatment-naive NSCLC patients presenting PD-L1 negative non-squamous disease.
The therapeutic combination delivered substantial progression-free survival benefits and favorable overall survival trends compared to the comparator group. Comprehensive findings are anticipated at the ESMO conference this October.
BMO Capital maintains a $142 valuation on MRK. Scotiabank projects a higher $155 target, supported by an enhanced cash flow multiple in their financial modeling. MRK currently trades close to its 52-week peak of $130.29.
AstraZeneca is simultaneously advancing laroprovstat, a rival oral PCSK9 inhibitor, suggesting Lipfendra’s first-to-market positioning may face competition within a compressed timeframe.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
